Three Lakes 12-20

12-20: the normal breaths-per-minute for healthy adults. Three Lakes 12-20 (TL12-20) is a public IPF/ILD Research Foundation created to carry on the mission and vision of Three Lakes 12-20's predecessor, Three Lakes Foundation (TLF). The primary goal is to advance therapies for Pulmonary Fibrosis (PF) and interstitial lung disease (ILD). TL12-20 strives to serve as a catalyst for uniting research, industries, and philanthropy to develop human-based translational tools and to fund the most promising safe and effective treatments. Three Lakes 12-20's predecessor, Three Lakes Foundation, was created by a family tragically affected by idiopathic pulmonary fibrosis (IPF), a form of pulmonary fibrosis with an unknown cause. Driven by their own frustrations with misdiagnoses, lack of information, poor treatment options, and limited oxygen access, they focused on changing the course of care for future patients, caregivers, and physicians. Although Three Lakes Foundation is sunsetting, Three Lakes 12-20 will operate within New Venture Fund, which is a free-standing 501(c)(3) public charity that will help to accomplish our mission. Until every person can breathe freely, we refuse to sit still. Three Lakes 12-20 Mission: To accelerate development of effective therapies and translational resources for Pulmonary Fibrosis and ILD. Vision: to develop new therapies for Pulmonary Fibrosis and ILD by bridging the most promising ideas with clinical validation. Advisory Board Mr. Sean Tully Dr. Paul Yaworsky Dr. Anna Podolanczuk Scientific Board (SAB) Dr. Andrew Limper